One of the major complications after allogeneic stem cell transplantation (SCT) in patients with malignant disease is a high frequency of relapse. We have prospectively analyzed the clinical impact of recipient-derived chimeric cells in 30 patients with acute myeloid leukemia and myelodysplastic syndrome after SCT. In order to improve sensitivity and specificity, all samples were cell-separated by using immunomagnetic beads according to the patient's leukemia phenotype, expressed at diagnosis or relapse before SCT. Twelve out of 30 patients experienced a clinical relapse after SCT. Median follow-up time for patients alive and without relapse (n = 15) was 30 (16-47) months. Mixed chimerism in peripheral blood (PB) and bone marrow (BM) у1 month post SCT, in the leukemia-affected cell lineage, was detected in 14/30 patients. Ten of these 14 patients relapsed as compared to 2/16 with donor chimerism (DC) (P Ͻ0.01). All eight patients with MC in peripheral blood у1 month after SCT relapsed vs 4/22 DC patients (P Ͻ 0.001). MC was detected a median of 66 (23-332) days before hematological relapse. No correlation was found between T cell MC and relapse. In this study, chimerism analysis showed a higher sensitivity and specificity vs morphological examination. In conclusion, this study may provide a rational basis for treatment with adoptive immunotherapy at an earlier time after SCT than at present, in patients with AML and MDS, in order to treat recurrences of malignant disease. Leukemia (2001Leukemia ( ) 15, 1976Leukemia ( -1985 
Introduction
Allogeneic stem cell transplantation (SCT) has become an important treatment for patients with hematological malignancies. It may induce remission in patients with otherwise refractory disease. 1 However, relapse of the primary malignancy remains the most frequent cause of treatment failure in patients in early and more advanced stages of the disease. 2 In those with recurrence of disease, immunotherapy has introduced the possibility of cure, but only few patients with acute leukemia will respond. 3 In those with CML, patients with a relapse detected only at the molecular or cytogenetic level show a better response to donor lymphocyte infusion (DLI) than those with hematological evidence of disease. 4, 5 In those with acute leukemia and myelodysplastic syndromes (MDS), early detection of patients at risk of a threatening relapse followed by adoptive immunotherapy, may prevent a hematological relapse. 6 Currently, a patient is considered in remission when less than 5% blast cells are detected by morphologic examination of the bone marrow (BM). At diagnosis, patients with acute leukemia may have a total of 10 12 malignant cells in the body. 7 Thus, a patient considered in remission may still harbor up to 10 10 malignant cells. 8 It is therefore important to develop sensitive and specific techniques which enable early detection of leukemia relapse and administration of additional immunotherapy -ie tapering of immunosuppression and administration of DLI.
In patients with acute myeloid leukemia (AML), the polymerase chain reaction (PCR) on translocation breakpoints with sensitivity of 10 −4 -10 −6 , permits monitoring of minimal residual disease (MRD). 9 However, translocation breakpoints can only be found in a minority of patients with AML. 8 Therefore, chimerism analysis, using PCR amplification of variable number of tandem repeats (VNTRs), which can be applied in almost all patients after SCT, may be an option. Whether mixed chimerism (MC) analysis -ie persistence of recipientderived hematopoietic cells, can be used as a tool for early detection of leukemia relapse post SCT, has been debated. 10 In some studies, no correlation has been found between MC and relapse in patients with acute leukemia. [11] [12] [13] However, high levels or increasing amounts of recipient cells after SCT, have been correlated with an increased risk of relapse by other investigators. [14] [15] [16] [17] Immunological phenotyping is regarded as an essential method for diagnosing and classifying acute leukemia. 18 Among patients with AML, almost all subtypes, according to the French-American-British (FAB) Cooperative Group classification, express CD13 and CD33. 19 In the present study, all samples were cell-separated by using immunomagnetic beads according to patients' leukemia phenotype, mainly CD13 and CD33, expressed at diagnosis or relapse before the transplant. In addition, all patients were also cell-separated for T and B cells. Our aim was to find out whether this approach would increase the sensitivity and specificity of chimerism analysis in patients with AML and MDS after SCT, thus permitting early detection of leukemia relapse.
Materials and methods

Patients
Between 16 October 1996 and 20 May 1999, 43 patients with AML or MDS underwent allogeneic SCT at the Center for Allogeneic Stemcell Transplantation, Huddinge University Hospital. Thirteen patients were excluded for leukemia lineagespecific chimerism analysis because of transplant-related mortality before day 100 post SCT (eight patients), no available blood samples (two patients) or no informative primer pair (three patients). Twenty-two patients with AML, six with MDS or MDS-AML, one with juvenile myelomonocytic leukemia and one patient with biphenotypic acute leukemia (Table 1) were included in the study. All results of the chimerism analysis were kept blinded, therefore no modification of treatment due to chimerism status was done. Median patient age was 33 (0.6-54) years. Twelve patients received SCT from HLAidentical siblings, 15 from HLA-A, -B and -DR compatible unrelated donors (MUD) and three patients from major mismatched unrelated donors. HLA-class I typing was performed serologically and class I subtyping, and class II typing, were performed genomically. 20 Cyclophosphamide (Cy), 60 mg/kg on 2 consecutive days (−5 and −4 or −4 and −3), combined with 10 Gy of total body irradiation (TBI) (with the lungs shielded to receive no more than 9 Gy), was given to 16 patients. In addition, one patient received etoposide (30 mg/kg). Five patients received fractionated (f) TBI (3 Gy × 4) and one patient, with a major mismatched unrelated donor, was given fTBI (3.6 Gy × 4), combined with Cy 60 mg/kg on 2 days. 21 The remaining eight patients received a combination of busulfan (4 mg/kg/day × 4) and Cy (60 mg/kg) on 2 consecutive days. In addition, one patient received melphalan (6 mg/kg). 22 Prior to SCT, patients with major mismatched donors (n = 3), MUD transplants (n = 15) or HLA-identical related donors (n = 2) received treatment with antithymocyte globuline (ATG) (IMTIX, Sangstat, Lyon, France) 2 mg/kg/day or OKT-3 (Janssen-Cilag, Zug, Switzerland) 5 mg/day for 5 days (days −5 to −1). 23 Patients with AML M4 or M5 or patients with a previous history of CNS leukemia, were given two 12 mg doses of intrathecal methotrexate (MTX) pre-SCT. Three patients received a T cell-depleted (TcD) graft, due to transplantation with mismatched unrelated SCT. TcD was performed with magnetic beads coupled with anti-CD2, CD3 and CD8 monoclonal antibodies (Dynal, Oslo, Norway). 24 All patients in this study, except one who was given cyclosporine A (CsA) alone, received CsA combined with a short course of MTX as GVHD prophylaxis. 25 Details regarding the transplantation procedure and supportive care have been published elsewhere.
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Definition of remission and relapse
Patients were, in general, analyzed with morphology of bone marrow (BM) aspirates at 3, 6 and 12 months and then yearly post SCT (Figures 1 and 2 ). All results were obtained from the Department of Pathology, Huddinge University Hospital. A patient with regenerating peripheral blood (PB) values was considered in clinical remission when less than 5% blast cells among 200 nucleated cells were found in a BM sample, on morphological examination. Clinical leukemic relapse was defined as at least 30% blast cells in BM aspirates, or presence of extramedullary leukemic cells -ie extramedullary relapse (EMR). If more than 5% but less than 30% blast cells were detected in BM, this was defined as an early relapse (ER). Patients with MDS were divided into MDS 1-MDS 5, according to the guidelines of the FAB Cooperative Group classification.
Specimens and PCR amplification template preparations
Peripheral blood (PB) samples were generally collected from the donor and recipient before transplantation and from the recipient, on days +14, +21 and +28 and monthly thereafter post SCT. In most patients, samples were also taken at 1.5 and 2.5 months as well. Bone marrow (BM) was examined in most, Leukemia but not all patients (Figures 1 and 2 ). DNA from donor and recipient pretransplantation samples was extracted, using standard protocols (Qiagen, Hilden, Germany). To evaluate leukemia lineage-specific chimerism, according to leukemia phenotype expressed at diagnosis or relapse prior to transplant, cell-separation was performed by using immunomagnetic beads as recommended by the manufacturer (Dynal). In all samples, cell-separation of CD19-and CD3-positive cells was performed first and then according to the leukemia immunophenotype of each patient, shown in Table 1 -ie CD2 or CD7 (n = 7) and CD13 or CD33 (n = 28). For separation of CD7-, CD13-and CD33-positive cells, PB or BM was incubated with mouse anti-human monoclonal antibodies (Dakopatts, Glostrup, Denmark) recognizing CD7 + , CD13 + and CD33
+ cells. Then, Pan-mouse-IgG-Dynabeads (Dynal) were added. After incubation for 20 min the cells were collected according to the manufacturer's instructions (Dynal). In two patients, CD45 was used as the myeloid marker. To each cell pellet, 30 l 10 mM Tris buffer was added before freezing. After thawing, 60 l lysis buffer (18 l 5× red cell lysis buffer (1.6 M sucrose, 0.05 M Tris-HCl, 25 mM MgCl 2 -6H 2 O, 5% Triton-X-100, 0.01 M Tris-Base), 8 l proteinase K (10 mg/ml), 34 l dH 2 O) was added to each bead-separated sample. Samples were then digested at 37°C overnight on a shaker. CD19-positive cell-separated samples were diluted in 100-300 l 10mM Tris buffer, pH 6.6. CD2-, CD3-, CD7-, CD13-, CD33-and CD45-positive cell-separated samples were diluted in 1000 l 10 mM Tris buffer, pH 6.6. Before PCR, diluted cell lysate samples were heated to 70°C for 10 min, spun for 1 min at 10 000 r.p.m. in a microcentrifuge and cooled on ice. For chimerism analysis, PCR amplification was performed using 10 ng of genomic DNA or 2 l (10-20 ng) of cell lysate DNA. Genomic DNA concentrations were measured in a Gene Quant II spectrophotometer (Pharmacia, Uppsala, Sweden), but cell lysate DNA was estimated by a semiquantitative dotMETRIC assay (NMI, San Diego, CA, USA). ) in the initial screening process before SCT, to find an informative locus separating the donor and the recipient. Data concerning the VNTR primers used in this study are shown in Table 2 . All oligonucleotide primers were synthesized commercially (Cybergene, Huddinge, Sweden). Each final PCR reaction (10 l) contained 0.5 M of each primer, 200 M of each dNTP (Perkin Elmer, Branchburg, CA, USA), 1× PCR buffer (1.5 mM MgCl, 50 mM Mg, 10 mM KCl, 0.001% gelatin), 5% glycerol, 1 g cresol red, 10-20 ng genomic DNA, 0.3 U AmpliTaq polymerase (Perkin Elmer). After an initial 3 min hot-start/denaturation step at 94°C, 32 PCR amplification cycles were carried out in a PTC-200 thermal cycler (MJ Research, Watertown, CA, USA). The first 10 amplification cycles were done in a two-segment step at 94°C for 15 s and at 65°C for 1 min. The following 22 cycles were done in a three-segment step at 94°C for 15 s, 61°C for 50 s and 72°C for 30 s. PCR amplified products were run on a ready-to-use PAGE system (Pharmacia Biotech, Uppsala, Sweden).12.5% non-denaturing polyacrylamide gels were run for 1.5 h under standard buffer conditions at 10°C in a Genephor peltier-cooled gel apparatus (Pharmacia). PCR amplified band patterns were analyzed in visible light after a Comparison of mixed chimerism (MC) in peripheral blood (PB) and bone marrow (BM) after cell separation according to the leukemia phenotype over time in patients with AML and MDS who relapsed after allogeneic SCT. Donor chimerism (DC). CR indicates complete remission, judged by morphological examination of bone marrow aspirates.
VNTR analysis
90 min automated silver staining procedure (Pharmacia Biotech). We used a semiquantitative estimation of MC, where recipient-band intensity and donor-band intensity were compared to dilution experiments in the patient and donor. Results were estimated and subdivided on a three-degree scale, 1-5%, 5-20% and Ͼ20%. After digital photodocumentation, PAGE gels were sealed in hybridization bags and stored at 4°C, for future reference.
Sensitivity of leukemia lineage-specific chimerism analysis
The sensitivity of detection for all five different VNTR primer pairs is shown in Table 2 . When using the PCR to amplify VNTR, preferential amplification of small allelic products relative to large allelic products has been described. 33 To obtain the same sensitivity for patients in this study, all except two yielded the smaller allelic product. We have previously reported an increased sensitivity of 2 × 10 −4 when CD19-positive cells were collected in a leukemia-affected cell lineagespecific manner, thus reducing the irrelevant background. 34, 35 In this study, in a cellular dilution series, myeloid leukemic cells (HL60) expressing CD33 were diluted in whole EDTA blood of a healthy individual with a known WBC. After cellseparation for the leukemia expressed phenotype CD33, a sensitivity of 4 × 10 −4 was obtained ( Figure 3 ). The percentage of CD33-positive cells in the donor was 0.5% of total white blood cell count.
Statistical analysis
Statistical analysis was performed using Fisher's exact test. The probability of relapse in the donor and mixed chimeric groups was calculated with the Kaplan-Meier product-limit method. 36 The differences between the two groups were compared with the log-rank test. 37 The sensitivity, specificity and positive and negative predictive values were calculated according to methods published elsewhere.
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Results
Patients
All patients in this study engrafted. The median follow-up time was 30 (16-47) months for patients alive and without hematological relapse (Table 1) . Fifteen patients remain alive and in complete remission (50%). Twelve patients (40%) have relapsed since SCT with a median time to relapse of 8.4 (1.8-12.8) months. Ten patients had a relapse in the marrow and two suffered an EMR. Three patients died of causes unrelated to relapse, two of pneumonia (UPN 689 and 658) and one due to GVHD (UPN 578). UPN 672, who relapsed after SCT, has received a second transplant. UPN 614, who had a poor graft function, received a second T cell-depleted (TcD) PBSCT without additional conditioning.
Figure 2
Comparison of mixed chimerism (MC) in peripheral blood (PB) and bone marrow (BM) after cell separation according to the leukemia phenotype over time in patients with AML and MDS in complete remission after allogeneic SCT. Donor chimerism (DC). Arrow indicates administration of PBSCT (UPN 614) due to poor graft function and DLI (UPN 629) due to suspected recurrence detected by morphological examination of bone marrow aspirates after SCT.
Correlation of leukemia lineage-specific chimerism analysis and relapse
Mixed chimerism in PB and/or BM у1 month following SCT, in cell-separated lineages according to leukemia phenotype, was detected in 14 patients, as shown in Figures 1 and 2 . Ten of these 14 patients subsequently relapsed vs 2/16 DC patients (P Ͻ 0.01). In all those with a verified relapse after SCT, the immunophenotype used for chimerism analysis was expressed by the leukemic clone at the time of relapse. In three patients (UPN 666, 633 and 604) who subsequently relapsed, MC was also detected in the aberrant CD7-positive clone together with Leukemia MC in the myeloid fraction. In two patients (UPN 686 and 672), one with an EMR and one with a BM relapse, all samples analyzed showed DC alone in the myeloid and the aberrant CD7-fraction. At the time of EMR, the morphological finding showed that UPN 686 was in CR in the BM. In UPN 672, in whom recipient cells were detected only in BM and not in PB at the time of relapse 8.2 months after SCT, no BM sample was available at 6 months for chimerism analysis. In UPN 693 and 604, with an EMR, no leukemic cells were detected in BM on morphological examination at the time of relapse. However, both patients showed an increasing MC on chimerism analysis in BM. Mixed chimerism in PB у1 month after SCT was seen in eight patients, all of whom subsequently relapsed vs 4/22 DC patients (P Ͻ 0.001), as illustrated in Figure 4 . Four patients with MC, still in CR, showed only MC in BM. In three of these (UPN 659, 656 and 601), MC was detected only 3 months after SCT, whereas UPN 614 has continued to show MC in the BM. In all, MC in leukemia-affected cell lineage was detected in 10/12 patients with a morphologically verified relapse. In 7/10 patients, MC was detected only in the leukemia-affected cell lineage at the time of relapse. The interval between detection of MC in the leukemia immunophenotype-separated cell lineages and relapse was 66 days (23-332). The sensitivity, specificity and positive and negative predictive values for predicting relapse for chimerism analysis of PB alone and PB and/or BM, are shown in Table 3 .
Chimerism status within CD3
+ and CD19
+ separated cells
Mixed chimerism in CD3-positive cells at any given time after SCT was detected in 15/30 (50%) patients (data not shown). In seven patients, of whom three relapsed, T cell MC was detected only during the first month after transplant. Seven of 12 patients (58%), who subsequently relapsed, showed T cell MC at any time after SCT vs 8/18 (44%) in CR (NS). Of the VNTR, variable number of tandem repeats; Chrom. location, chromosome location; Het., heterozygosity; Informativeness, proportion of patdon pairs with separable alleles in 110 pairs (siblings + unrelated).
Figure 3
Sensitivity of mixed chimerism analysis (MC) in leukemia-specific cell lineage using VNTR D1S80. Myeloid leukemic cells (HL60) expressing CD33 were diluted in whole EDTA blood of a healthy subject with known WBCs followed by immunomagnetic immobilization of CD33-positive cells. Immobilized cells were lysed and PCR was performed directly on cell lysate DNA. The percentage of CD33-positive cells in the donor was 0.5% of total white blood cell count. three patients with a late relapse (Ͼ300 days after SCT), two showed T cell MC after SCT until days +87 and +403, respectively. However, one of these two patients, UPN 604, had a biphenotypic acute leukemia. Overall, MC in the B cell fraction (CD19 + cells) was detected in 4/30 (13%) patients, of whom three relapsed after SCT. In one patient, UPN 605, the leukemic clone at the time of relapse showed an aberrant expression of CD19.
Morphology
Early relapse (ER) was detected in five patients (UPN 563, 656, 629, 689 and 601), shown in Figures 1 and 2 by morphological examination. One of these (UPN 563) has relapsed clinically. In two patients (UPN 666 and 682) with ER detected on days +77 and +380, these days were defined as endpoints in the study, since ER was clinically considered a relapse. In the four patients with 'false positive' ER (UPN 656, 629, 689 and 601), only UPN 629 received additional treatment -ie a donor lymphocyte infusion (10 6 /kg). The sensitivity, specificity and positive and negative predictive values for BM aspirates with Ͼ5% to Ͻ30% blasts for predicting relapse are shown in Table 3 . In UPN 605, who had a hematological relapse 1.8
Leukemia months after SCT, no BM aspirate was taken before the relapse was confirmed. Therefore, this patient was excluded from the analysis.
Discussion
Relapse is the most frequent cause of treatment failure in patients with acute leukemia after allogeneic SCT. 2 The 3-year probability of relapse in patients in first complete remission may be as high as 30%. 40 In patients with more advanced disease, the 3-year probability of relapse is even higher. 2 Adoptive immunotherapy by DLI has been successful in the treatment of relapse in patients with CML, but less successful in those with acute leukemia. 3 This may be partly because acute leukemia generally develops within a shorter period than chronic leukemia, thus patients with acute leukemia may develop a greater tumor burden. It is well established that there is a close relationship between the tumor burden and the likelihood of curing acute leukemia. 41 It is also known that in CML patients with a relapse after SCT, the success of DLI is related to the tumor burden. 42 It is therefore important to develop sensitive and specific techniques which will permit early detection of a leukemia relapse after SCT.
In patients with AML and MDS, PCR on translocation breakpoints may be used to detect MRD after SCT. 43 However, this approach can be used in only 20-30% of patients with AML. 8 Chimerism analysis, which can be used in almost all patients, may therefore be an alternative for early detection of recurrence of malignant disease after SCT. There has been a debate as to whether chimerism analysis can be used in this approach. 11, 12, 16, 17 Partly, this may be explained by long time intervals between specimens taken after SCT, which increase the risk of missing a rapidly developing MC before the actual relapse. Indeed, Bader et al 15 showed that MC was significantly correlated to relapse when samples were taken at very short intervals after SCT. Another way to increase the sensitivity and specificity of chimerism analysis is to analyze cell subsets. We have previously shown, by reducing the irrelevant background, that the sensitivity is increased by two logs when CD19
+ cells are analyzed separately in patients with pre-B-ALL and B-CLL after SCT. 34, 35 This has also been found by others. [44] [45] [46] Thiede and co-workers 47 have also recently shown that high sensitivity may be achived after cell separation of CD34 + cells, thus enabling early detection of leukemia relapse after SCT. Because of the controversy concerning the value of Cumulative incidence of relapse in patients with mixed chimerism (MC) vs patients with donor chimerism (DC) in peripheral blood (PB) in patients with AML and MDS after allogeneic SCT. chimerism analysis, it is important to optimize the diagnostic protocols. If the best methods could be found they might form the basis of general technical standards.
In this study, the aim was to analyze chimerism status in leukemia-specific cell subsets, after cell-separation according to the leukemia phenotype expressed at diagnosis or relapse before SCT. In all patients except two, CD13 or CD33 were used as leukemia-specific markers. These markers are also expressed by almost all AML subtypes according to FAB. 19 In dilution experiments, we also found an increased sensitivity reaching 4 × 10 , with this approach. In this study, MC was detected in 10 patients before the relapse was verified morphologically. In one patient with EMR, MC was not seen at all in PB and BM. In patients with ALL, MRD analysis of BM is also unreliable for predicting EMR. 48 However, in two patients in this study, both suffering from EMR after SCT, an increase in the MC pattern in BM was found, indicating an impending relapse. In UPN 672, with MC detected only in the BM at the time of relapse 8 months after SCT, no BM sample was available at 6 months for chimerism analysis. A critical transitional MC may therefore have been missed. In three patients (UPN 601, 656 and 659) with MC detected only in BM at 3 months, no relapse occurred. In two (UPN 601 and 656) of these, BM morphology showed 10% blast cells at the same time. In the third patient (UPN 659), the morphological findings were uncertain at 3 months. In all three patients, immunosuppression was tapered at this time. They also developed acute and chronic GVHD after SCT. It is well known that there is a correlation between GVHD and graftversus-leukemia effect (GVL). 40 These patients may therefore have harbored leukemic cells in the BM at this time, which disappeared due to GVL. It has also been suggested that analyzes of BM samples are more sensitive than PB samples in patients with AML. 43, 49 Another possibility is that MC detected in the BM in these patients, is due to contamination of normal recipient-derived stromal cells. Simmons et al 50 reported that potentially contaminating cells were often of recipient origin, but macrophages were exclusively of donor origin. UPN 614 continued to have MC in the leukemia-affected cell lineage in BM. This patient also developed acute and chronic GVHD after SCT and was given a second TcD PBSCT due to poor graft function. In a study by Potter et al, 51 relapse developed in two patients with ALL more than 8 years after positive MRD post-treatment results, suggesting that leukemic cells may persist in a quiescent state for years before causing a clinical relapse. Whether this patient has a stable MC of normal recipient-derived cells or remnants of the leukemic clone needs further follow-up. In contrast, UPN 633 showed MC in PB but not in BM at 3 months post SCT. This may have been due to a poor BM aspirate or bad sample handling.
In this study, no correlation was found between T cell MC and relapse. This has also been described by others. 12 In 7/10 patients whose MC was detected before relapse, MC was detected only in the leukemia-affected cell lineage. This finding of complete donor chimerism in all cell subsets analyzed, except the leukemia-affected cell lineage, has been noted before. 52, 53 The only patients with MC in the T cell fraction at the time of relapse in this study were those with an aberrant CD7 expression before SCT. It has been suggested that immune escape by clonal evolution of the leukemia is a common occurrence in patients who relapse with myeloid leukemias after SCT. 54 There are several explanations why leukemic cells may escape strong immune reactions like GVHD. 55 The expression of HLA class I and class II may be reduced, thus inhibiting recognition by donor T cells. 56 Other explanations could be insufficient expression of adhesion molecules and low production of proinflammatory cytokines.
In many centers today, the standard assessment of the leukemia follow-up after SCT relies on morphological examination. In this study, we show that this approach not only has lower sensitivity but also lower specificity than chimerism analysis. In UPN 629 and 689, both with complete DC in PB and BM, ER was detected by morphological examination at 6 months after SCT. Thus, in both patients several BM aspirates were taken after this finding due to fear of a threatening relapse but all of them showed CR. UPN 629 also received DLI due to the ER result. By chimerism analysis in the leukemia-specific cell lineages, we detected MC at a median of 2 months before overt relapse. This time-gap may be important for successful additional immunotherapy. For example, in UPN 666, chimerism analysis revealed an almost complete autologous pattern 70 days after SCT in the leukemia-affected cell lineage, but morphologically the patient was still considered to be in remission. However, it should be noted that 5/18 patients without a clinical relapse, were not analyzed with chimerism analysis in BM. Only 8/18 patients were examined with chimerism analysis in BM during the first 6 months post SCT. The specificity of chimerism analysis in PB combined with BM may therefore be lower than in this study. From the data presented in this study, additional immunotherapy -ie tapering of immunosuppression followed by DLI, if needed, may be given when MC is detected in the leukemiaaffected cell lineage in PB Ͼ1 month after SCT. Bader et al 6, 57 have also reported promising results using this approach. However, more data from different laboratories are needed to evaluate the impact of MC in BM and also in PB before any definite treatment recommendations can be made. If possible, chimerism analysis should be combined with PCR on translocation breakpoints, to increase specificity before decisionmaking. This has also been proposed by others. 35, 44 In conclusion, analysis of MC in the leukemia-affected cell lineage of patients with AML and MDS is a sensitive and specific method which enables early detection of leukemia relapse after allogeneic SCT. This study may provide a rational basis for treatment with adoptive immunotherapy at an earlier time after SCT than at present, in order to treat recurrences of malignant disease.
